FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1333-1341 April 3, 2003 Number 14 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease.

Methods Patients with moderate-to-severe Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev). The secondary efficacy end points included the Severe Impairment Battery and other measures of cognition, function, and behavior. Treatment differences between base line and the end point were assessed. Missing observations were imputed by using the most recent previous observation (the last observation carried forward). The results were also analyzed with only the observed values included, without replacing the missing values (observed-cases analysis).

Results Two hundred fifty-two patients (67 percent women; mean age, 76 years) from 32 U.S. centers were enrolled. Of these, 181 (72 percent) completed the study and were evaluated at week 28. Seventy-one patients discontinued treatment prematurely (42 taking placebo and 29 taking memantine). Patients receiving memantine had a better outcome than those receiving placebo, according to the results of the CIBIC-Plus (P=0.06 with the last observation carried forward, P=0.03 for observed cases), the ADCS-ADLsev (P=0.02 with the last observation carried forward, P=0.003 for observed cases), and the Severe Impairment Battery (P<0.001 with the last observation carried forward, P=0.002 for observed cases). Memantine was not associated with a significant frequency of adverse events.

Conclusions Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.

Glutamate is the principal excitatory neurotransmitter in the brain.^6,7 Glutamatergic overstimulation may result in neuronal damage, a phenomenon that has been termed excitotoxicity. Such excitotoxicity ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative disorders.⁸ Glutamate stimulates a number of postsynaptic receptors, including the N-methyl-D-aspartate (NMDA) receptor, which has been particularly implicated in memory processes, dementia, and the pathogenesis of Alzheimer's disease.^9,10,11

Memantine, an uncompetitive NMDA-receptor antagonist, could be of therapeutic value in Alzheimer's disease.¹² A recent study in patients with advanced dementia (Alzheimer's disease and vascular dementia) suggested therapeutic benefits.¹³ Accordingly, we conducted a trial of the efficacy of memantine in outpatients with moderate-to-severe Alzheimer's disease.

Methods

Patients

Patients at least 50 years old who were residing in the community and had probable Alzheimer's disease according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)⁴ and of the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association¹⁴ were recruited. The eligibility criteria included base-line Mini–Mental State Examination scores of 3 to 14,¹⁵ a stage of 5 or 6 on the Global Deterioration Scale,¹⁶ and a stage of 6a or greater on the Functional Assessment Staging instrument,¹⁷ signifying the presence of dementia-related deficits in the ability to perform one or more basic activities of daily living. The patients had reliable caregivers and had undergone computed tomography (CT) or magnetic resonance imaging (MRI) of the brain within the previous 12 months.

Patients with vascular dementia, dementia or clinically significant neurologic disease due to conditions other than Alzheimer's disease, major depressive disorder, or a score greater than 4 on the modified Hachinski Ischemic Rating Scale¹⁸ were excluded. Patients with clinically significant coexisting medical conditions or laboratory abnormalities were also excluded, as were patients receiving specific concomitant medications (anticonvulsant agents, antiparkinsonian agents, hypnotic agents, anxiolytic agents, neuroleptic agents, cholinomimetic agents, or any other investigational compounds). Patients who had been receiving stable antidepressant treatment for at least two months were eligible, and chloral hydrate could be used as a sedative or hypnotic, but not within 24 hours before an assessment.

Study Design

In this 28-week, double-blind, parallel-group study, patients were randomly assigned to receive either memantine (20 mg per day; Merz) or an identical-appearing placebo. Randomization was stratified according to site with the use of RanCode (version 3.1) and in blocks of four, with staff at the individual sites blinded to the randomization process. The assigned treatment was discontinued if continuation represented a medical risk in the opinion of the study physician, or if the patient declined ongoing participation. Subjects who withdrew prematurely were asked to complete end-point measures at the time of early termination and to return at 28 weeks for a "retrieved-dropout visit," which included all end-point assessments. The results of an optional 24-week open-label study extension, in which all patients took memantine, are still being analyzed.

Thirty-two U.S. centers participated. The trial was conducted in compliance with the Declaration of Helsinki and its amendments and was approved by study-center institutional review boards. The eligible patients and responsible caregivers provided written informed consent.

Merz Pharmaceuticals provided study medication and funding and was involved in planning the design and protocol. Data analysis was performed by a contract research organization (Quintiles), along with the authors. The data are stored at Merz Pharmaceuticals.

Efficacy Variables

The prespecified primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) global score (New York University version)¹⁹ at 28 weeks and the change from base line to week 28 in the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)²⁰ modified for more severe dementia (ADCS-ADLsev).²¹ If values from the 28-week observation were not available, the last observed value was used. Assessments were conducted at base line, at mid-study (week 12), and at the end of treatment (week 28) or at early termination, with a 28-week retrieved-dropout visit when possible.

The CIBIC-Plus measures overall global change relative to base line and is scored on a seven-point scale ranging from 1 (markedly improved) to 7 (markedly worse). The domains of cognition (assessed by patient interview), function (caregiver interview), and behavior (separate patient and caregiver interviews) are systematically evaluated. Experienced clinicians, blinded to adverse events and other study assessments, conducted separate interviews with study patients and caregivers to assess overall change on the CIBIC-Plus. To ensure consistency, the same clinician completed all CIBIC-Plus interviews for each study patient and associated caregiver wherever possible.

The ADCS-ADL is a structured questionnaire originally created to assess functional capacity over a broad range of severity of dementia. Each item consists of a series of hierarchical questions designed to determine a patient's ability to perform one of the activities of daily living, ranging from total independence to total inability. A subgroup of 19 individually validated items (the ADCS-ADLsev) was used; a total score of 54 signified optimal performance, and lower scores indicated worse performance. Caregivers assessed a patient's activities during the preceding four-week interval. The differences in total scores were analyzed.

In addition, six other efficacy variables were measured. The Severe Impairment Battery^22,23 was designed to evaluate cognitive performance in advanced Alzheimer's disease. A 51-item scale, it assesses social interaction, memory, language, visuospatial ability, attention, praxis, and construction. The scores range from 0 (greatest impairment) to 100. The Severe Impairment Battery was part of a predefined responder analysis. The Mini–Mental State Examination¹⁵ is a 30-point scale that measures cognitive function, with higher scores indicating better function. The Global Deterioration Scale¹⁶ is a seven-stage scale that assesses overall cognitive and functional capacity on the basis of observations of the patient and reports from the caregiver. Higher stages signify greater impairment.

The Functional Assessment Staging scale¹⁷ assesses the magnitude of progressive functional deterioration in patients with dementia by identifying characteristic progressive disabilities. Its seven major stages range from normal (stage 1) to severe dementia (stage 7). Five substages in stage 6, corresponding to the loss of ability to independently dress, bathe, and handle proper mechanics and cleanliness in using the toilet, and to remain continent, respectively, of urine and feces and six substages in stage 7, corresponding to the loss of speech, ambulation, and other motor capacities, are assessed. The Neuropsychiatric Inventory²⁴ assesses neuropsychiatric disturbances with a 12-item scale based on information from the caregiver regarding the patient's behavior and associated distress felt by the caregiver. The scores range from 0 to 144 for the patient-assessment rating and from 0 to 60 for the caregiver-distress rating, with 0 indicating the optimum in each case. The Resource Utilization in Dementia²⁵ instrument was designed to assess the burden on the caregiver and to provide Alzheimer's disease–related health economics data through structured interviews with caregivers. To assess the clinical relevance of treatment effects further, a multifactor responder analysis was predefined.

Measures of safety, assessed at specified intervals, included neurologic and physical examinations, measurement of vital signs, electrocardiography, laboratory tests (hematologic tests, blood chemical values, and urinalysis), and recording of adverse events.

Statistical Analysis

The main efficacy analysis was based on the randomized patients who received at least one assessment after base line. This analysis included both those who completed the study and those who discontinued their assigned treatment prematurely. For the latter, the efficacy observation at week 28 was imputed from the last available observation carried forward.²⁶ Three additional analyses were also performed to adjust for missing values. One analysis was identical to the primary analysis, except that the actual retrieved-dropout values at week 28 were used when available. A second analysis included patients for whom no value after base line was available in addition to the intention-to-treat population and assumed no change in the outcome measures for these patients. In the third analysis, missing values were replaced for those with no value after base line by the mean observed value for decline in the placebo group. An observed-cases analysis was also performed based on data for all randomized patients who were available for evaluation at week 28.

Efficacy outcomes were analyzed by application of the Wilcoxon–Mann–Whitney test for independent samples to the change from base line. There were no interim analyses. The prespecified group with an individual response was defined as the patients who improved or had no deterioration on the CIBIC-Plus and who improved or had no deterioration on either the ADCS-ADLsev or the Severe Impairment Battery. All patients were included in the safety analysis. All reported P values are two-sided.

Results

Study Population

Of 345 patients screened between August 1998 and April 1999 at 32 U.S. centers, 252 were randomly assigned to study groups. Seventy-one of the patients (42 of the 126 assigned to placebo and 29 of the 126 assigned to memantine) discontinued their assigned treatment before week 28, and the remaining 181 completed the double-blind portion of the study. Five patients were excluded from the analysis of the ADCS-ADLsev results and 16 from the analysis of the CIBIC-Plus results because they had not been assessed after the base-line assessment. The mean (±SD) duration of treatment for both groups was 24±8 weeks. Only 5 of the 71 patients who left the study returned for a retrieved-dropout visit at week 28. Premature discontinuations were due to adverse events in 22 of the patients in the placebo group (17 percent) and 13 of the patients in the memantine group (10 percent). Other major reasons for discontinuation included the patient's refusal of ongoing participation (14 patients receiving placebo [11 percent] and 12 patients receiving memantine [10 percent]), death (4 patients receiving placebo [3 percent] and 1 patient receiving memantine [1 percent]), protocol violation (3 patients receiving placebo [2 percent] and 3 patients receiving memantine [2 percent]), and change of caregiver (2 patients receiving placebo [2 percent] and none receiving memantine). Patients could have multiple reasons for discontinuation.

The base-line characteristics were similar in the two treatment groups (Table 1). Of the randomized patients, 67 percent were female, and the mean age was 76 years. The mean base-line score on the Mini–Mental State Examination for the study population was 7.9.

View this table: [in this window] [in a new window]   Table 1. Base-Line Characteristics of the Intention-to-Treat Population.

 
Efficacy

The base-line scores and the results based on analyses with the last observation carried forward and analyses of observed cases for the efficacy variables are shown in Table 2. The CIBIC-Plus ratings at the end point (mean difference between the groups, 0.3; P=0.06) and week 28 (mean difference, 0.3; P=0.03) supported the effectiveness of memantine (Figure 1A).

View this table: [in this window] [in a new window]   Table 2. Results of the Efficacy Analysis.

 

View larger version (15K): [in this window] [in a new window]   Figure 1. Primary Efficacy Variables. The mean (±SE) scores at each specified time in the observed-cases analysis are shown. The boxes indicate the mean (±SE) at the end point in the analysis with the last observation carried forward in the intention-to-treat population. Panel A shows the change from base line in the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) global scores. Panel B shows the change from base line in the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory, modified for severe dementia (ADCS-ADLsev).

 
The total ADCS-ADLsev scores at base line were similar in the two groups (27.4 in the placebo group and 26.8 in the memantine group) (Table 2). At the end point and at week 28 (Figure 1B), there was significantly less deterioration in the memantine group than in the placebo group (in the analysis with the last observation carried forward, the mean difference was 2.1 [P=0.02]; in the observed-cases analysis, the mean difference was 3.4 [P=0.003]).

The Severe Impairment Battery showed significant differences favoring memantine (P<0.001 with the last observation carried forward, P=0.002 for observed cases) (Figure 2A). On the basis of the predetermined definition of a response in the study protocol, 29 percent of the patients receiving memantine and 10 percent of those receiving placebo had a response (P<0.001).

View larger version (16K): [in this window] [in a new window]   Figure 2. Other Efficacy Variables. The mean (±SE) scores at each specified time in the observed-cases analysis are shown. The boxes indicate the mean (±SE) at the end point in the analysis with the last observation carried forward in the intention-to-treat population. Panel A shows the change from base line in Severe Impairment Battery (SIB) scores. Panel B shows the change from base line in Functional Assessment Staging (FAST) scores, calculated by enumerating the stages and substages as follows: stage 3 (–2) through stage 5 (0) and substage 6a (1) through substage 7f (11).

 
Memantine-treated patients showed significantly less deterioration in their functional Alzheimer's disease stage, as measured by the Functional Assessment Staging score (P=0.02 with the last observation carried forward, P=0.007 for observed cases) (Figure 2B). In the analysis of the intention-to-treat population with the last observation carried forward and at week 28 no significant differences were observed between treatment groups in the Mini–Mental State Examination score, Global Deterioration Scale stage, or Neuropsychiatric Inventory score.

Additional analyses were performed with different strategies used for missing values, as described above. The results were unchanged in each of these analyses.

A subgroup analysis examined whether efficacy was seen in both patients with moderate Alzheimer's disease (Mini–Mental State Examination score, 10 to 14) and those with severe Alzheimer's disease (Mini–Mental State Examination score, less than 10). A benefit of memantine as compared with placebo was suggested for all outcome measures in both groups.

The required caregiver time, as assessed by the Resource Utilization in Dementia score, was analyzed in the intention-to-treat population with the last observation carried forward. The result was statistically significant, indicating that caregivers spent less time with patients receiving memantine (difference between treatment groups, 45.8 hours per month; 95 percent confidence interval, 10.37 to 81.27; P=0.01).

Safety and Tolerability

As expected in this population with moderate-to-severe illness, the majority of patients had adverse events during the study (84 percent with memantine and 87 percent with placebo). However, most adverse events were mild to moderate in severity and were either not related or unlikely to be related to the study medication (Table 3). The incidence rates for the frequently reported adverse events in the memantine group were no more than 2 percent higher than in the placebo group. There were no clinically relevant differences between patients in the memantine and placebo groups in base-line assessments of clinical laboratory values, electrocardiographic results, or measurements of vital signs.

View this table: [in this window] [in a new window]   Table 3. Most Frequently Reported Adverse Events.

 
More patients receiving placebo than patients receiving memantine discontinued the study prematurely because of adverse events (22 [17 percent] vs. 13 [10 percent]). Agitation was the most common reason for discontinuation (7 percent of those receiving placebo and 5 percent of those receiving memantine). Serious adverse events were reported in 23 patients receiving placebo (18 percent) and 16 patients receiving memantine (13 percent). There were seven deaths, two of which occurred in the memantine group. Two of these patients died within the 30-day period after the last dose of study medication. Most of the serious adverse events, including all of the deaths, were considered to be unrelated to the study medication.

Discussion

This study provides evidence that modulation of NMDA receptors to reduce glutamate-induced excitotoxicity alleviates the symptoms of Alzheimer's disease. This novel neurochemical approach is distinct from the cholinomimetic mechanism of all currently approved treatments for Alzheimer's disease.

This trial studied patients whose moderate-to-severe Alzheimer's disease compromised their ability to perform both instrumental and basic activities of daily living independently.¹⁷ More than 95 percent of patients were in Functional Assessment Staging stage 6. All patients had difficulty putting on clothing independently, and many also had difficulties with handling the mechanics of bathing and toilet use, and some patients also had difficulties maintaining continence. The significant differences observed in favor of the memantine group on the ADCS-ADLsev, the Functional Assessment Staging ratings, and the Severe Impairment Battery suggest reduced decline in these critical capacities, which was apparent in the global assessment of the patients (CIBIC-Plus in the observed-cases analysis).

The clinical relevance of treatment effects has been an issue in all trials of medication for Alzheimer's disease. Point differences between drug- and placebo-treated patients on quantitative scales do not necessarily indicate that these effects are clinically meaningful. Response analyses (rates of individual response) are often performed to illustrate the clinical relevance of results. In the present study, a significant difference in the predefined criterion for a response, which incorporated multiple end points, was observed. The treatment effects seen in the areas of cognition and function seemed to translate into improvements in the patients' behavior (less agitation in the adverse-events reports) and mitigation of the burden on caregivers (fewer hours spent assisting the patient).

The results of the present study cannot be directly compared with those of studies of other antidementia drugs (tacrine, donepezil, rivastigmine, and galantamine); virtually all published studies with these compounds have been performed in patients with mild-to-moderate Alzheimer's disease. An exception is a recent study of donepezil by Feldman et al.²⁷ However, even that study included patients with less severe disease (the mean Mini–Mental State Examination score at base line was 12) than those in the present trial, whose mean Mini–Mental State Examination score at base line was less than 8. The treatment effects of memantine in the present study and donepezil in the study by Feldman et al. are of similar size for the common end points, the CIBIC-Plus and the Severe Impairment Battery. Cholinergic compounds have gastrointestinal side effects, whereas the tolerability of memantine in this study was found to be excellent. Future studies will need to examine whether memantine treatment and cholinergic treatment may ultimately prove to be complementary or even synergistic.

There are notable limitations to this study. The dropout rate for the total study population was 28 percent, which is probably attributable to the relatively severe stage of disease in the study patients. The withdrawal rate was higher in the placebo group (33 percent) than in the memantine group (23 percent). The failure to obtain information at week 28 for the majority of patients who discontinued the study prematurely limits the interpretation of the results. However, the average duration of randomly assigned therapy for patients in this 28-week trial was 24 weeks for both study groups. In three analyses, the effects of different strategies for replacing missing observations for all patients assigned to treatment were investigated, and the results did not change materially. Thus, our data indicate that memantine reduces decline in patients with moderate-to-severe Alzheimer's disease.

Supported by Merz Pharmaceuticals, Frankfurt, Germany. Methodologic procedures and development of measurements were supported by grants (AG-03051, AG-08051, and 1-U01 AG-10483) from the National Institute on Aging of the National Institutes of Health.

Dr. Reisberg, Dr. Doody, and Dr. Ferris report having received lecture fees from Lundbeck. Dr. Ferris reports having received lecture fees from Forest and Merz. Dr. Doody and Dr. Ferris report having received consulting fees from Forest and Lundbeck. Dr. Schmitt reports having received consulting fees from Forest.

We are indebted to Yvonne Wirth, M.D., for statistical support.

^* The members of the Memantine Study Group are listed in the Appendix.

Source Information

From the Department of Psychiatry, New York University School of Medicine, New York (B.R., S.F.); the Department of Neurology, Baylor College of Medicine, Houston (R.D.); Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.J.M.); and the Departments of Neurology and Psychiatry, University of Kentucky, Lexington (F.S.).

Address reprint requests to Dr. Reisberg at the William and Sylvia Silberstein Aging and Dementia Research and Treatment Center, New York University School of Medicine, 550 First Ave., New York, NY 10016, or at barry.reisberg{at}med.nyu.edu.

References

1. Khachaturian ZS. Plundered memories. Sciences 1997;37(4):20-5. 
2. Reisberg B, Burns A, Broadty H, et al. Diagnosis of Alzheimer's disease: report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int Psychogeriatr 1997;9:Suppl 1:11-38. [Medline]
3. Henderson AS, Jorm AF. Definition and epidemiology of dementia: a review. In: Maj M, Sartorius N, eds. Dementia. 2nd ed. Chichester, England: John Wiley, 2002:1-33.
4. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
5. Physicians' desk reference. 56th ed. Montvale, N.J.: Medical Economics, 2002:1270-3, 1351-5, 1792-6, 2342-8, 2665-7.
6. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984;42:1-11. [Web of Science][Medline]
7. Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993;56:539-555. [CrossRef][Web of Science][Medline]
8. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622. [Free Full Text]
9. Shimizu E, Tang YP, Rampon C, Tsien JZ. NMDA receptor-dependent synaptic re-inforcement is a crucial process for memory consolidation. Science 2000;290:1170-1174. [Erratum, Science 2001;291:1902.] [Free Full Text]
10. Ackerley S, Grierson AJ, Brownlees J, et al. Glutamate slows axonal transport of neurofilaments in transfected neurons. J Cell Biol 2000;150:165-176. [Free Full Text]
11. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders: focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998;116:421-437. [Web of Science][Medline]
12. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. Neuroprotective and symptomalogical action of memantine relevant for Alzheimer's disease — a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000;2:85-98.
13. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (benefit and efficacy in severely de-mented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146. [CrossRef][Web of Science][Medline]
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. [Free Full Text]
15. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198. [CrossRef][Web of Science][Medline]
16. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139. [Free Full Text]
17. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 1992;4:Suppl 1:55-69. [CrossRef][Medline]
18. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488. [CrossRef][Web of Science][Medline]
19. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11:Suppl 3:8-18.
20. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S33-S39.
21. Galasko DR, Schmitt FA, Jin S, et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 2000;21:Suppl 1:S168-S168. abstract. 
22. Panisset M, Roudier M, Saxton J, Boller F. Severe Impairment Battery: a neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-45. [Free Full Text]
23. Schmitt FA, Ashford W, Ernesto C, et al. The Severe Impairment Battery: concurrent validity and assessment of longitudinal change in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S51-S56.
24. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314. [Free Full Text]
25. Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health economics of dementia. Chichester, England: John Wiley, 1998:465-99.
26. Gillings D, Koch G. The application of the principle of intent-to-treat to the analysis of clinical trials. Drug Inf J 1991;25:411-424. 
27. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620. [Erratum, Neurology 2001;57:2153.] [Free Full Text]

The following were members of the Memantine Study Group: J.T. Apter, Princeton Biomedical Research, Princeton, N.J.; B. Baumel, Baumel–Eisner Neuromedical Institute, Fort Lauderdale, Fla.; C. Bernick, Nevada School of Medicine, Las Vegas; J.S. Carman, Carman Research, Smyrna, Ga.; L.P. Charles, Southern New Jersey Medical Institute, Stratford; J. Corey-Bloom, University of California, San Diego; H. Cummins, Institute for Advanced Clinical Research, Elkins Park, Pa.; C. DeCarli, University of Kansas Medical Center, Kansas City; R. Duara, Wien Center for Alzheimer's Disease, Miami Beach, Fla.; E. DuBoff, Denver Center for Medical Research, Denver; N. Edwards, University of Tennessee, Memphis; L. Eisner, Baumel–Eisner Neuromedical Institute, Fort Lauderdale, Fla.; M.R. Farlow, Indiana University Center for Alzheimer's Disease, Indianapolis; S. Flitman, Neurology Group, Phoenix, Ariz.; R.H. Hubbard, Southwest Institute for Clinical Research, Rancho Mirage, Calif.; A. Jacobson, Neurological Consultants, Hollywood, Fla.; C.L. Jurkowski, Hampton Hospital, Westhampton Township, N.J.; A. Kiev, Life Span Develop Mental Systems, Poughkeepsie, N.Y.; L.C. Kirby II, Medici Resarch Centers, Peoria, Ariz.; D. Margolin, 6335 N. Fresno St., Fresno, Calif.; C. Merideth, Affiliated Research Institute, San Diego, Calif.; J.E. Mintzer, Alzheimer's Research and Clinical Program, Charleston, S.C.; E. Pfeiffer, University of South Florida Suncoast Gerontology Center, Tampa; R. Richter, St. John's Doctor's Building, Tulsa, Okla.; C.H. Sadowsky, Premiere Research Institute, West Palm Beach, Fla.; P. Solomon, Memory Clinic, Bennington, Vt.; S. Targum, Clinical Studies, Philadelphia; H. Tilker, Four Rivers Clinical Research, Paducah, Ky.; and M. Usman, Alzheimer's Center of Pittsburgh, Pittsburgh.

Abstract PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Related Letters:

Memantine in Moderate-to-Severe Alzheimer's Disease
Bleich S., Wiltfang J., Kornhuber J., Reisberg B., Doody R., Möbius H. J.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:609-610, Aug 7, 2003. Correspondence

This article has been cited by other articles:

• Lagreze, W A, Feltgen, N, Bach, M, Jehle, T (2009). Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 93: 1667-1671 [Abstract] [Full Text]  
• de Jonghe, J F M, Wetzels, R B, Mulders, A, Zuidema, S U, Koopmans, R T C M (2009). Validity of the Severe Impairment Battery Short Version. J. Neurol. Neurosurg. Psychiatry 80: 954-959 [Abstract] [Full Text]  
• Lyoo, I. K., Yoon, S. J., Musen, G., Simonson, D. C., Weinger, K., Bolo, N., Ryan, C. M., Kim, J. E., Renshaw, P. F., Jacobson, A. M. (2009). Altered Prefrontal Glutamate-Glutamine-{gamma}-Aminobutyric Acid Levels and Relation to Low Cognitive Performance and Depressive Symptoms in Type 1 Diabetes Mellitus. Arch Gen Psychiatry 66: 878-887 [Abstract] [Full Text]  
• Winblad, B. (2009). Review: Donepezil in Severe Alzheimer's Disease. AM J ALZHEIMERS DIS OTHER DEMEN 24: 185-192 [Abstract]  
• Smith, D. A. (2009). Treatment of Alzheimer's disease in the long-term-care setting. Am J Health Syst Pharm 66: 899-907 [Abstract] [Full Text]  
• Coba, M. P., Pocklington, A. J., Collins, M. O., Kopanitsa, M. V., Uren, R. T., Swamy, S., Croning, M. D. R., Choudhary, J. S., Grant, S. G. N. (2009). Neurotransmitters Drive Combinatorial Multistate Postsynaptic Density Networks. Sci Signal 2: ra19-ra19 [Abstract] [Full Text]  
• SALLOWAY, S., CORREIA, S. (2009). Alzheimer disease: Time to improve its diagnosis and treatment. Cleveland Clinic Journal of Medicine 76: 49-58 [Abstract] [Full Text]  
• Herrmann, N. MD, Gauthier, S. MD (2008). Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 179: 1279-1287 [Abstract] [Full Text]  
• Jalbert, J. J., Daiello, L. A., Lapane, K. L. (2008). Dementia of the Alzheimer Type. Epidemiol Rev 30: 15-34 [Abstract] [Full Text]  
• Saddichha, S., Pandey, V. (2008). Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies. AM J ALZHEIMERS DIS OTHER DEMEN 23: 150-161 [Abstract]  
• Qaseem, A., Snow, V., Cross, J. T. Jr., Forciea, M. A., Hopkins, R. Jr., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., Santaguida, P., Owens, D. K., the Joint American College of Physicians/American, (2008). Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. ANN INTERN MED 148: 370-378 [Abstract] [Full Text]  
• Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., Oremus, M. (2008). Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. ANN INTERN MED 148: 379-397 [Abstract] [Full Text]  
• Riemer, C., Burwinkel, M., Schwarz, A., Gultner, S., Mok, S. W. F., Heise, I., Holtkamp, N., Baier, M. (2008). Evaluation of drugs for treatment of prion infections of the central nervous system. J. Gen. Virol. 89: 594-597 [Abstract] [Full Text]  
• Caselli, R. J., Yaari, R. (2008). Medical Management of Frontotemporal Dementia. AM J ALZHEIMERS DIS OTHER DEMEN 22: 489-498 [Abstract]  
• Maidment, I. D, Fox, C. G, Boustani, M., Rodriguez, J., Brown, R. C, Katona, C. L (2008). Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis. The Annals of Pharmacotherapy 42: 32-38 [Abstract] [Full Text]  
• Mitchell, S. L. (2007). A 93-Year-Old Man With Advanced Dementia and Eating Problems. JAMA 298: 2527-2536 [Abstract] [Full Text]  
• Brayne, C., Fox, C., Boustani, M. (2007). Dementia Screening in Primary Care: Is It Time?. JAMA 298: 2409-2411 [Full Text]  
• Zhu, L.-Q., Wang, S.-H., Liu, D., Yin, Y.-Y., Tian, Q., Wang, X.-C., Wang, Q., Chen, J.-G., Wang, J.-Z. (2007). Activation of Glycogen Synthase Kinase-3 Inhibits Long-Term Potentiation with Synapse-Associated Impairments. J. Neurosci. 27: 12211-12220 [Abstract] [Full Text]  
• Cummings, J. L., Doody, R., Clark, C. (2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69: 1622-1634 [Abstract] [Full Text]  
• Gray, J. A., Roth, B. L. (2007). Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia. Schizophr Bull 33: 1100-1119 [Abstract] [Full Text]  
• Swanson, K. A., Carnahan, R. M. (2007). Dementia and Comorbidities: An Overview of Diagnosis and Management. Journal of Pharmacy Practice 20: 296-317 [Abstract]  
• Black, S. E., Doody, R., Li, H., McRae, T., Jambor, K. M., Xu, Y., Sun, Y., Perdomo, C. A., Richardson, S. (2007). Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69: 459-469 [Abstract] [Full Text]  
• Yesavage, J., Hoblyn, J., Friedman, L., Mumenthaler, M., Schneider, B., O'Hara, R. (2007). Should One Use Medications in Combination With Cognitive Training? If So, Which Ones?. J Gerontol B Psychol Sci Soc Sci 62: 11-18 [Abstract] [Full Text]  
• (2007). References. APPI Online CME 2007: 2-2 [Full Text]  
• De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., Klein, W. L. (2007). Abeta Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine. J. Biol. Chem. 282: 11590-11601 [Abstract] [Full Text]  
• Lexchin, J. (2007). Different conclusions about memantine. cfp 53: 403-404 [Full Text]  
• Massoud, F. (2007). Response. cfp 53: 404-404 [Full Text]  
• Blaszczyk, A. T., Mathys, M. (2007). Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia. Journal of Pharmacy Practice 20: 13-28 [Abstract]  
• Massoud, F. (2007). Maladie d'Alzheimer. cfp 53: 50-54 [Abstract] [Full Text]  
• Jin, L., Sugiyama, H., Takigawa, M., Katagiri, D., Tomitori, H., Nishimura, K., Kaur, N., Phanstiel, O. IV, Kitajima, M., Takayama, H., Okawara, T., Williams, K., Kashiwagi, K., Igarashi, K. (2007). Comparative Studies of Anthraquinone- and Anthracene-Tetraamines as Blockers of N-Methyl-D-aspartate Receptors. J. Pharmacol. Exp. Ther. 320: 47-55 [Abstract] [Full Text]  
• Chiappelli, F., Navarro, A. M., Moradi, D. R., Manfrini, E., Prolo, P. (2006). Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease. Evid Based Complement Alternat Med 3: 411-424 [Abstract] [Full Text]  
• Hewett, S. J., Silakova, J. M., Hewett, J. A. (2006). Oral Treatment with Rofecoxib Reduces Hippocampal Excitotoxic Neurodegeneration. J. Pharmacol. Exp. Ther. 319: 1219-1224 [Abstract] [Full Text]  
• Burns, A., O'Brien, J. (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 20: 732-755 [Abstract]  
• Farlow, M. R. (2006). Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease. Mayo Clin Proc. 81: 1350-1358 [Abstract] [Full Text]  
• Friedlander, A. H., Norman, D. C., Mahler, M. E., Norman, K. M., Yagiela, J. A. (2006). Alzheimer's disease: Psychopathology, medical management and dental implications.. Journal of the American Dental Association 137: 1240-1251 [Abstract] [Full Text]  
• Gauthier, S., Herrmann, N., Ferreri, F., Agokou, C. (2006). Use of memantine to treat Alzheimer's disease.. CMAJ 175: 501-502 [Full Text]  
• Cummings, J. L., Schneider, E., Tariot, P. N., Graham, S. M., for the Memantine MEM-MD-02 Study Group, (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.. Neurology 67: 57-63 [Abstract] [Full Text]  
• Reisberg, B., Doody, R., Schmitt, F., Ferris, S. (2006). Open-Label Extension Studies and Misinformation--Reply. Arch Neurol 63: 1036-1037 [Full Text]  
• Scharre, D. W. (2006). Galantamine With Adjunctive Memantine: Combined Effects on Brain Nicotinic Acetylcholine Receptors and N-methyl-D-aspartate Receptors May Improve Alzheimer's Disease Symptomatology. J Clin Pharmacol 46: 6S-7S [Full Text]  
• Geerts, H., Grossberg, G. T. (2006). Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. J Clin Pharmacol 46: 8S-16S [Abstract] [Full Text]  
• Grossberg, G. T., Edwards, K. R., Zhao, Q. (2006). Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease. J Clin Pharmacol 46: 17S-26S [Abstract] [Full Text]  
• Creeley, C., Wozniak, D. F., Labruyere, J., Taylor, G. T., Olney, J. W. (2006). Low Doses of Memantine Disrupt Memory in Adult Rats. J. Neurosci. 26: 3923-3932 [Abstract] [Full Text]  
• Unger, C., Svedberg, M. M., Yu, W.-F., Hedberg, M. M., Nordberg, A. (2006). Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice. J. Pharmacol. Exp. Ther. 317: 30-36 [Abstract] [Full Text]  
• Sheehan, B., Saad, K. (2006). Service innovations: a dedicated drug treatment service for dementia. The Psychiatrist 30: 146-148 [Abstract] [Full Text]  
• Qin, S., Colin, C., Hinners, I., Gervais, A., Cheret, C., Mallat, M. (2006). System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40.. J. Neurosci. 26: 3345-3356 [Abstract] [Full Text]  
• Yucel, Y. H., Gupta, N., Zhang, Q., Mizisin, A. P., Kalichman, M. W., Weinreb, R. N. (2006). Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.. Arch Ophthalmol 124: 217-225 [Abstract] [Full Text]  
• Huerta, P. T., Kowal, C., DeGiorgio, L. A., Volpe, B. T., Diamond, B. (2006). Immunity and behavior: Antibodies alter emotion. Proc. Natl. Acad. Sci. USA 103: 678-683 [Abstract] [Full Text]  
• Cummings, J. L. (2006). What We Can Learn From Open-Label Extensions of Randomized Clinical Trials. Arch Neurol 63: 18-19 [Full Text]  
• Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., Mobius, H. J. (2006). A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease. Arch Neurol 63: 49-54 [Abstract] [Full Text]  
• Chiba, T., Yamada, M., Hashimoto, Y., Sato, M., Sasabe, J., Kita, Y., Terashita, K., Aiso, S., Nishimoto, I., Matsuoka, M. (2005). Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotrophic Factor to Its N Terminus: Characterization of Colivelin-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults In Vitro and In Vivo. J. Neurosci. 25: 10252-10261 [Abstract] [Full Text]  
• Rosenberg, R. N. (2005). Translational Research on the Way to Effective Therapy for Alzheimer Disease. Arch Gen Psychiatry 62: 1186-1192 [Abstract] [Full Text]  
• Farlow, M. R. (2005). Moderate to severe Alzheimer disease: Definition and clinical relevance. Neurology 65: S1-S4 [Full Text]  
• Feldman, H. H., Woodward, M. (2005). The staging and assessment of moderate to severe Alzheimer disease. Neurology 65: S10-S17 [Abstract] [Full Text]  
• Cummings, J. L. (2005). Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease. Neurology 65: S18-S24 [Full Text]  
• Farlow, M. R. (2005). The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence. Neurology 65: S25-S30 [Full Text]  
• Chen, H.-S. V., Lipton, S. A. (2005). Pharmacological Implications of Two Distinct Mechanisms of Interaction of Memantine with N-Methyl-D-aspartate-Gated Channels. J. Pharmacol. Exp. Ther. 314: 961-971 [Abstract] [Full Text]  
• Sleeper, R. B (2005). Antipsychotic Dose-Sparing Effect with Addition of Memantine. The Annals of Pharmacotherapy 39: 1573-1576 [Abstract] [Full Text]  
• Ridha, B. H., Josephs, K. A., Rossor, M. N. (2005). Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine. Neurology 65: 481-482 [Abstract] [Full Text]  
• Vandenberghe, R, Tournoy, J (2005). Cognitive aging and Alzheimer's disease. Postgrad. Med. J. 81: 343-352 [Abstract] [Full Text]  
• Banerjee, P., Samoriski, G., Gupta, S. (2005). Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons". J. Pharmacol. Exp. Ther. 313: 928-929 [Full Text]  
• Aracava, Y., Pereira, E. F. R., Maelicke, A., Albuquerque, E. X. (2005). Response: Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons". J. Pharmacol. Exp. Ther. 313: 930-933 [Full Text]  
• Yao, C., Raoufinia, A., Gold, M., Nye, J. S., Ramael, S., Padmanabhan, M., Walschap, Y., Verhaeghe, T., Zhao, Q. (2005). Steady-State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects. J Clin Pharmacol 45: 519-528 [Abstract] [Full Text]  
• Takano, J., Tomioka, M., Tsubuki, S., Higuchi, M., Iwata, N., Itohara, S., Maki, M., Saido, T. C. (2005). Calpain Mediates Excitotoxic DNA Fragmentation via Mitochondrial Pathways in Adult Brains: EVIDENCE FROM CALPASTATIN MUTANT MICE. J. Biol. Chem. 280: 16175-16184 [Abstract] [Full Text]  
• Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., Lee, L., Bannister, C., Elvish, R., Jacoby, R. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330: 874- [Abstract] [Full Text]  
• Floden, A. M., Li, S., Combs, C. K. (2005). {beta}-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor {alpha} and NMDA Receptors. J. Neurosci. 25: 2566-2575 [Abstract] [Full Text]  
• Molinuevo, J. L., Llado, A., Rami, L. (2005). Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. AM J ALZHEIMERS DIS OTHER DEMEN 20: 77-85 [Abstract]  
• Ellis, J. M. (2005). Cholinesterase Inhibitors in the Treatment of Dementia. JAOA: Journal of the American Osteopathic Association 105: 145-158 [Abstract] [Full Text]  
• Aracava, Y., Pereira, E. F. R., Maelicke, A., Albuquerque, E. X. (2005). Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons. J. Pharmacol. Exp. Ther. 312: 1195-1205 [Abstract] [Full Text]  
• Peltz, G., Pacific, D. M., Noviasky, J. A., Shatla, A., Mehalic, T. (2005). Seizures associated with memantine use. Am J Health Syst Pharm 62: 420-421 [Full Text]  
• Sink, K. M., Holden, K. F., Yaffe, K. (2005). Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence. JAMA 293: 596-608 [Abstract] [Full Text]  
• Samuels, M. A. (2005). Update in Neurology. ANN INTERN MED 142: 28-36 [Full Text]  
• Langa, K. M., Foster, N. L., Larson, E. B. (2004). Mixed Dementia: Emerging Concepts and Therapeutic Implications. JAMA 292: 2901-2908 [Abstract] [Full Text]  
• Minkeviciene, R., Banerjee, P., Tanila, H. (2004). Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer's Disease. J. Pharmacol. Exp. Ther. 311: 677-682 [Abstract] [Full Text]  
• Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., Kelly, M. E. M. (2004). An Investigation of the Neuroprotective Effects of Tetracycline Derivatives in Experimental Models of Retinal Cell Death. Mol. Pharmacol. 66: 1113-1122 [Abstract] [Full Text]  
• Belgeri, M., Morley, J. E. (2004). A Step Back in Time: Is There a Place for Older Drugs in the Treatment of Dementia?. J Gerontol A Biol Sci Med Sci 59: M1025-M1028 [Full Text]  
• Albensi, B. C., Igoechi, C., Janigro, D., Ilkanich, E. (2004). Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?. AM J ALZHEIMERS DIS OTHER DEMEN 19: 269-274 [Abstract]  
• Periclou, A. P, Ventura, D., Sherman, T., Rao, N., Abramowitz, W. T (2004). Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil. The Annals of Pharmacotherapy 38: 1389-1394 [Abstract] [Full Text]  
• Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Hux, M., Xu, Y., Schwam, E.M., Shah, S., Mastey, V. (2004). Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63: 644-650 [Abstract] [Full Text]  
• Cummings, J. L. (2004). Alzheimer's Disease. NEJM 351: 56-67 [Full Text]  
• Bloom, B. S., Chhatre, S., Jayadevappa, R. (2004). Cost effects of a specialized care center for people with Alzheimer's disease. AM J ALZHEIMERS DIS OTHER DEMEN 19: 226-232 [Abstract]  
• Rockwood, K (2004). Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75: 677-685 [Abstract] [Full Text]  
• Tariot, P. N. (2004). Memantine for Patients With Alzheimer Disease--Reply. JAMA 291: 1695-1695 [Full Text]  
• Ajilore, O. A., Kumar, A. (2004). Delirium and Dementia. Focus 2: 210-220 [Abstract] [Full Text]  
• Dall'Igna, O. P, Souza, D. O, Lara, D. R (2004). Caffeine as a Neuroprotective Adenosine Receptor Antagonist. The Annals of Pharmacotherapy 38: 717-718 [Full Text]  
• Harris, P. B., Keady, J. (2004). Editorial. Dementia 3: 5-7  
• Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I. (2004). Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. JAMA 291: 317-324 [Abstract] [Full Text]  
• Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., Greenberg, D. A. (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101: 343-347 [Abstract] [Full Text]  
• Molinuevo, J. L., Garcia-Gil, V., Villar, A. (2004). Memantine: An antiglutamatergic option for dementia. AM J ALZHEIMERS DIS OTHER DEMEN 19: 10-18 [Abstract]  
• Friedenberg, R. M. (2003). Dementia: One of the Greatest Fears of Aging. Radiology 229: 632-635 [Full Text]  
• Helmuth, L. (2003). Detangling Alzheimer's Disease. Sci Aging Knowl Environ 2003: oa2-2 [Abstract] [Full Text]  
• (2003). {blacktriangledown}Memantine for dementia?. DTB 41: 73-76 [Abstract] [Full Text]  
• Kawas, C. H. (2003). Early Alzheimer's Disease. NEJM 349: 1056-1063 [Full Text]  
• Bleich, S., Wiltfang, J., Kornhuber, J., Reisberg, B., Doody, R., Mobius, H. J. (2003). Memantine in Moderate-to-Severe Alzheimer's Disease. NEJM 349: 609-610 [Full Text]